Chemotherapy for Metastatic or Unresectable Bladder Cancer

Seminars in Oncology

Volumn 34, Issue 2, 2007, Pages 135-144

  Bellmunt, Joaquim ^a   Albiol, Santiago ^b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL QUIRÓN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IFOSFAMIDE; METHOTREXATE; OXALIPLATIN; PACLITAXEL; PEMETREXED; PIRITREXIM; TAXANE DERIVATIVE; TRIMETREXATE; VINBLASTINE; VINCA ALKALOID; VINFLUNINE;

ADVANCED CANCER; ARTICLE; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; ELDERLY CARE; FOLLOW UP; HUMAN; KIDNEY FUNCTION; METASTASIS; PHASE 3 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; RISK FACTOR; SALVAGE THERAPY; STANDARD; UROGENITAL TRACT TUMOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; SURVIVAL RATE; URINARY BLADDER NEOPLASMS;

EID: 33947276729     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2006.12.008     Document Type: Article

References (131)

1. Loehrer Sr. P.J., Einhorn L.H., Elson P.J., et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol 10 (1992) 1066-1073
2. Logothetis C.J., Dexeus F.H., Finn L., et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 8 (1990) 1050-1055
3. Bellmunt J., Ribas A., Eres N., et al. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer 80 (1997) 1966-1972
4. Sternberg C.N., Yagoda A., Scher H.I., et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 133 (1985) 403-407
5. Sternberg C.N., Yagoda A., Scher H.I., et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 64 (1989) 2448-2458
6. Harker W.G., Meyers F.J., Freiha F.S., et al., A Northern California Oncology Group study. Cisplatin, methotrexate, and vinblastine (CMV): An effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. J Clin Oncol 3 (1985) 1463-1470
7. Hillcoat B.L., Raghavan D., Matthews J., et al. A randomized trial of cisplatin versus cisplatin plus methotrexate in advanced cancer of the urothelial tract. J Clin Oncol 7 (1989) 706-709
8. Stoter G., Splinter T.A., Child J.A., et al. Combination chemotherapy with cisplatin and methotrexate in advanced transitional cell cancer of the bladder. J Urol 137 (1987) 663-667
9. Mead G.M., Russell M., Clark P., et al., MRC Advanced Bladder Cancer Working Party. A randomized trial comparing methotrexate and vinblastine (MV) with cisplatin, methotrexate and vinblastine (CMV) in advanced transitional cell carcinoma: Results and a report on prognostic factors in a Medical Research Council study. Br J Cancer 78 (1998) 1067-1075
10. Loehrer Sr. P.J., Elson P., Dreicer R., et al. Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: An Eastern Cooperative Oncology Group trial. J Clin Oncol 12 (1994) 483-488
11. Logothetis C.J., Finn L.D., Smith T., et al. Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: Results of a randomized trial. J Clin Oncol 13 (1995) 2272-2277
12. Scher H.I., Geller N.L., Curley T., et al. Effect of relative cumulative dose-intensity on survival of patients with urothelial cancer treated with M-VAC. J Clin Oncol 11 (1993) 400-407
13. Seidman A.D., Scher H.I., Gabrilove J.L., et al. Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer. J Clin Oncol 11 (1993) 408-414
14. Sternberg C.N., de Mulder P.H., Schornagel J.H., et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer protocol no. 30924. J Clin Oncol 19 (2001) 2638-2646
15. Bellmunt J., and Albiol S. New chemotherapy combinations for advanced bladder cancer. Curr Opin Urol 11 (2001) 517-522
16. Calabro F., and Sternberg C.N. New drugs and new approaches for the treatment of metastatic urothelial cancer. World J Urol 20 (2002) 158-166
17. Calabro F., and Sternberg C.N. High-risk metastatic urothelial cancer: Chances for cure?. Curr Opin Urol 12 (2002) 441-448
18. Saxman S.B., Propert K.J., Einhorn L.H., et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol 15 (1997) 2564-2569
19. Bellmunt J., Albanell J., Gallego O.S., et al. Carboplatin, methotrexate, and vinblastine in patients with bladder cancer who were ineligible for cisplatin-based chemotherapy. Cancer 70 (1992) 1974-1979
20. Waxman J., and Barton C. Carboplatin-based chemotherapy for bladder cancer. Cancer Treat Rev 19 suppl C (1993) 21-25
21. Culine S., Rebillard X., Iborra F., et al. Gemcitabine and oxaliplatin in advanced transitional cell carcinoma of the urothelium: A pilot study. Anticancer Res 23 (2003) 1903-1906
22. Font A., Esteban E., Carles J., et al. Gemcitabine and oxaliplatin combination: A multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer. J Clin Oncol 22 (2004) 392s (abstr 4544)
23. Moore M.J., Winquist E., Vokes E.E., et al. Phase II study of oxaliplatin in patients with inoperable, locally advanced or metastatic transitional cell carcinoma of the urothelial tract (TCC) who have received prior chemotherapy. Proc Am Soc Clin Oncol 22 (2004) 408 (abstr 1638)
24. Witte R.S., Elson P., Khandakar J., et al. An Eastern Cooperative Oncology Group phase II trial of trimetrexate in the treatment of advanced urothelial carcinoma. Cancer 73 (1994) 688-691
25. de Wit R., Kaye S.B., Roberts J.T., et al. Oral piritrexim, an effective treatment for metastatic urothelial cancer. Br J Cancer 67 (1993) 388-390
26. Khorsand M., Lange J., Feun L., et al. Phase II trial of oral piritrexim in advanced, previously treated transitional cell cancer of bladder. Invest New Drugs 15 (1997) 157-163
27. Dreicer R., Roth B., and Wilding G. Overview of advanced urothelial cancer trials of the Eastern Cooperative Oncology Group. Cancer 97 (2003) 2109-2114
28. Misset J.L. Brief communication: Use of the multitargeted antifolate pemetrexed (Alimta) in genitourinary cancer. Semin.Oncol 29 (2002) 36-39
29. Sternberg C.N. Gemcitabine in bladder cancer. Semin Oncol 27 (2000) 31-39
30. Sternberg C.N., and Vogelzang N.J. Gemcitabine, paclitaxel, pemetrexed and other newer agents in urothelial and kidney cancers. Crit Rev Oncol Hematol 46 suppl S (2003) 105-115
31. von der Maase H. Gemcitabine in transitional cell carcinoma of the urothelium. Exp Rev Anticancer Ther 3 (2003) 11-19
32. Artz A., Stadler W.M., Vogelzang N.J., et al. A phase II trial of sequential chemotherapy with docetaxel and methotrexate followed by gemcitabine and cisplatin for metastatic urothelial cancer. Am J Clin Oncol 28 (2005) 109-113
33. Moore M.J., Tannock I.F., Ernst D.S., et al. Gemcitabine: A promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol 15 (1997) 3441-3445
34. Stadler W.M., Kuzel T., Roth B., et al. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol 15 (1997) 3394-3398
35. Kaufman D., Raghavan D., Carducci M., et al. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol 18 (2000) 1921-1927
36. Moore M.J., Winquist E.W., Murray N., et al. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: A phase II trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 17 (1999) 2876-2881
37. von der Maase H., Andersen L., Crino L., et al. Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: A phase II clinical trial. Ann Oncol 10 (1999) 1461-1465
38. von der Maase H., Hansen S.W., Roberts J.T., et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18 (2000) 3068-3077
39. Burch P.A., Richardson R.L., Cha S.S., et al. Phase II study of paclitaxel and cisplatin for advanced urothelial cancer. J Urol 164 (2000) 1538-1542
40. Dreicer R., Manola J., Roth B.J., et al. Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: An Eastern Cooperative Oncology Group Study. J Clin Oncol 18 (2000) 1058-1061
41. Murphy B.A., Johnson D.R., Smith J., et al. Phase II trial of paclitaxel and cisplatin for metastatic or locally unresectable urothelial cancer. Proc Am Soc Clin Oncol 12 (1996) 245 (abstr 617)
42. Dimopoulos M.A., Bakoyannis C., Georgoulias V., et al. Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: A multicenter phase II study of the Hellenic Cooperative Oncology Group. Ann Oncol 10 (1999) 1385-1388
43. Garcia del Muro X., Marcuello E., Guma J., et al. Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer. Br J Cancer 86 (2002) 326-330
44. Sengelov L., Kamby C., Lund B., et al. Docetaxel and cisplatin in metastatic urothelial cancer: A phase II study. J Clin Oncol 16 (1998) 3392-3397
45. Bamias A., Aravantinos G., Deliveliotis C., et al. Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: A multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. J Clin Oncol 22 (2004) 220-228
46. Redman B.G., Smith D.C., Flaherty L., et al. Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma. J Clin Oncol 16 (1998) 1844-1848
47. Small E.J., Lew D., Redman B.G., et al. Southwest Oncology Group study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: the importance of survival as a clinical trial end point. J Clin Oncol 18 (2000) 2537-2544
48. Vaughn D.J., Malkowicz S.B., Zoltick B., et al. Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: An active and tolerable outpatient regimen. J Clin Oncol 16 (1998) 255-260
49. Dreicer R., Manola J., Roth B.J., et al. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. Cancer 100 (2004) 1639-1645
50. Petrioli R., Frediani B., Manganelli A., et al. Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomized phase II study. Cancer 77 (1996) 344-351
51. Carteni G., Dogliotti L., Crucitta E., et al. Phase II randomized trial of gemcitabine plus cisplatin (GP) and gemcitabine plus carboplatin (GC) in patients (pts) with advanced or metastatic transitional cell carcinoma of the urothelium (TCCU). J Clin Oncol 22 (2003) 384s (abstr 1543)
52. Bellmunt J., de Wit R., Albanell J., et al. A feasibility study of carboplatin with fixed dose of gemcitabine in "unfit" patients with advanced bladder cancer. Eur J Cancer 37 (2001) 2212-2215
53. Bajorin D.F., McCaffrey J.A., Dodd P.M., et al. Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: Final report of a phase II trial evaluating two dosing schedules. Cancer 88 (2000) 1671-1678
54. Dodd P.M., McCaffrey J.A., Hilton S., et al. Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract. J Clin Oncol 18 (2000) 840-846
55. Maluf F.C., and Bajorin D.F. Chemotherapy agents in transitional cell carcinoma: the old and the new. Semin Urol Oncol 19 (2001) 2-8
56. Novick S., Higgins G., Hilton S., et al. Phase I/II sequential doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with transitional cell carcinoma and impaired renal function. Proc Am Soc Clin Oncol 19 (2000) 361 (abstr 1423)
57. Bellmunt J., Guillem V., Paz-Ares L., et al., Spanish Oncology Genitourinary Group. Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. J Clin Oncol 18 (2000) 3247-3255
58. Hussain M., Vaishampayan U., Du W., et al. Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol 19 (2001) 2527-2533
59. Hainsworth J.D., Meluch A.A., Litchy S., et al. Paclitaxel, carboplatin, and gemcitabine in the treatment of patients with advanced transitional cell carcinoma of the urothelium. Cancer 103 (2005) 2298-2303
60. Edelman M.J., Meyers F.J., Miller T.R., et al. Phase I/II study of paclitaxel, carboplatin, and methotrexate in advanced transitional cell carcinoma: A well-tolerated regimen with activity independent of p53 mutation. Urology 55 (2000) 521-525
61. Tu S.M., Hossan E., Amato R., et al. Paclitaxel, cisplatin and methotrexate combination chemotherapy is active in the treatment of refractory urothelial malignancies. J Urol 154 (1995) 1719-1722
62. Pectasides D., Visvikis A., Aspropotamitis A., et al. Chemotherapy with cisplatin, epirubicin and docetaxel in transitional cell urothelial cancer. Phase II trial. Eur J Cancer 36 (2000) 74-79
63. Law L.Y., Lara P.N., Meyers F.J., et al. Platinum free combination chemotherapy in locally advanced and metastatic transitional cell carcinoma: Phase I/II trial of gemcitabine, paclitaxel, methotrexate. J Clin Oncol 20 (2001) 192a (abstr 767)
64. Dodd P.M., McCaffrey J.A., Herr H., et al. Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma. J Clin Oncol 17 (1999) 2546-2552
65. Bajorin D.F., Dodd P.M., Mazumdar M., et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 17 (1999) 3173-3181
66. Stadler W.M., Hayden A., von der Maase H., et al. Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer. Urol Oncol 7 (2002) 153-157
67. von der Maase H., Sengelov L., Roberts J.T., et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23 (2005) 4602-4608
68. Bellmunt J., Albanell J., Paz-Ares L., et al. Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine. Cancer 95 (2002) 751-757
69. Siefker-Radtke A.O., Millikan R.E., Tu S.M., et al. Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer. J Clin Oncol 20 (2002) 1361-1367
70. Linardou H., Aravantinos G., Efstathiou E., et al. Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group. Urology 64 (2004) 479-484
71. Turkolmez K., Beduk Y., Baltaci S., et al. Gemcitabine plus vinorelbine chemotherapy in patients with advanced bladder carcinoma who are medically unsuitable for or who have failed cisplatin-based chemotherapy. Eur Urol 44 (2003) 682-686
72. Vaughn D., Dreicer R., Manola J., et al. E2896 paclitaxel/carboplatin in advanced urothelial carcinoma and renal insufficiency: A phase II trial of the Eastern Cooperative Group. Proc Am Soc Clin Oncol 19 (2000) 343 (abstr 1351)
73. Ardavanis A., Tryfonopoulos D., Alexopoulos A., et al. Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: A phase II study. Br J Cancer 92 (2005) 645-650
74. Fechner G., Siener R., Reimann M., et al. Randomised phase II trial of gemcitabine and paclitaxel second-line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99). Int J Clin Pract 60 (2006) 27-31
75. Gitlitz B.J., Baker C., Chapman Y., et al. A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma. Cancer 98 (2003) 1863-1869
76. Guardino A.E., and Srinivas S. Gemcitabine and paclitaxel as second line chemotherapy for advanced urothelial malignancies. Proc Am Soc Clin Oncol 21 (2002) 150b (abstr 321)
77. Meluch A.A., Greco F.A., Burris III H.A., et al. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: A phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 19 (2001) 3018-3024
78. Parameswaran R., Fisch M.J., Ansari R.H., et al. A Hoosier Oncology Group phase II study of weekly paclitaxel and gemcitabine in advanced transitional cell (TCC) carcinoma of the bladder. Proc Am Soc Clin Oncol 20 (2001) (abstr 798)
79. Sternberg C.N., Calabro F., Pizzocaro G., et al. Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer 92 (2001) 2993-2998
80. Kaufman D.S., Carducci M.A., Kuzel T.M., et al. A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer. Urol Oncol 22 (2004) 393-397
81. Bellmunt J., Cos J., Cleries R., et al. Feasibility trial of methotrexate-paclitaxel as a second line therapy in advanced urothelial cancer. Cancer Invest 20 (2002) 673-685
82. Di Lorenzo G., Autorino R., Giordano A., et al. FOLFOX-4 in pre-treated patients with advanced transitional cell carcinoma of the bladder. Jpn J Clin Oncol 34 (2004) 747-750
83. Witte R.S., Elson P., Bono B., et al. Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. J Clin Oncol 15 (1997) 589-593
84. McCaffrey J.A., Hilton S., Mazumdar M., et al. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol 15 (1997) 1853-1857
85. de Wit R., Kruit W.H., Stoter G., et al. Docetaxel (Taxotere): An active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients. Br J Cancer 78 (1998) 1342-1345
86. Paz-Ares L., Tabernero J., Moyano A., et al. A phase II of the multi-targeted antifolate, MTA (LY231514), in patients with advanced transitional cell carcinoma of the bladder. Proc Am Soc Clin Oncol 14 (1998) 339 (abstr 1307)
87. Sweeney C., Roth B.J., Kaufman D.S., et al. Phase II study of pemetrexed (pem) for second-line treatment of transitional cell cancer (tcc) of the bladder. Proc Am Soc Clin Oncol 22 (2003) 411 (abstr 1653)
88. Bui C., Theodore S., Culine E., et al. Preliminary results of a phase II study testing intravenous (iv) vinflunine (VFL) as second line therapy in patients with advanced transitional cell cancer (TCC) of the bladder. Proc Am Soc Clin Oncol 22 (2003) 391 (abstr 1571)
89. Bellmunt J., Hussain M., and Dinney C.P. Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family. Crit Rev Oncol Hematol 46 suppl (2003) S85-S104
90. Geller N.L., Sternberg C.N., Penenberg D., et al. Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy. Cancer 67 (1991) 1525-1531
91. Lord R.V., Brabender J., Gandara D., et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 8 (2002) 2286-2291
92. Petrylak D.P., Scher H.I., Reuter V., et al. P-glycoprotein expression in primary and metastatic transitional cell carcinoma of the bladder. Ann Oncol 5 (1994) 835-840
93. Pendyala L., Velagapudi S., Toth K., et al. Translational studies of glutathione in bladder cancer cell lines and human specimens. Clin Cancer Res 3 (1997) 793-798
94. Siu L.L., Banerjee D., Khurana R.J., et al. The prognostic role of p53, metallothionein, P-glycoprotein, and MIB-1 in muscle-invasive urothelial transitional cell carcinoma. Clin Cancer Res 4 (1998) 559-565
95. Cordon-Cardo C., Zhang Z.F., Dalbagni G., et al. Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. Cancer Res 57 (1997) 1217-1221
96. Esrig D., Elmajian D., Groshen S., et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 331 (1994) 1259-1264
97. Zhang Z.T., Pak J., Huang H.Y., et al. Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation. Oncogene 20 (2001) 1973-1980
98. Sarkis A.S., Bajorin D.F., Reuter V.E., et al. Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. J Clin Oncol 13 (1995) 1384-1390
99. Chow N.H., Chan S.H., Tzai T.S., et al. Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clin Cancer Res 7 (2001) 1957-1962
100. Neal D.E., Marsh C., Bennett M.K., et al. Epidermal-growth-factor receptors in human bladder cancer: Comparison of invasive and superficial tumours. Lancet 1 (1985) 366-368
101. Inoue K., Kamada M., Slaton J.W., et al. The prognostic value of angiogenesis and metastasis-related genes for progression of transitional cell carcinoma of the renal pelvis and ureter. Clin Cancer Res 8 (2002) 1863-1870
102. Izawa J.I., Sweeney P., Perrotte P., et al. Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis. Clin Cancer Res 8 (2002) 1258-1270
103. Slaton J.W., Inoue K., Perrotte P., et al. Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma. Am J Pathol 158 (2001) 735-743
104. Slaton J.W., Millikan R., Inoue K., et al. Correlation of metastasis related gene expression and relapse-free survival in patients with locally advanced bladder cancer treated with cystectomy and chemotherapy. J Urol 171 (2004) 570-574
105. Al-Sukhun S., and Hussain M. Current understanding of the biology of advanced bladder cancer. Cancer 97 (2003) 2064-2075
106. Raghavan D. Molecular targeting and pharmacogenomics in the management of advanced bladder cancer. Cancer 97 (2003) 2083-2089
107. Salonga D.S., Danenberg K.D., Grem J., et al. Relative gene expression in normal and tumor tissue by quantitative RT-PCR. Methods Mol Biol 191 (2002) 83-98
108. Rosell R., Taron M., Ariza A., et al. Molecular predictors of response to chemotherapy in lung cancer. Semin Oncol 31 (2004) 20-27
109. Selvakumaran M., Pisarcik D.A., Bao R., et al. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res 63 (2003) 1311-1316
110. Dabholkar M., Bostick-Bruton F., Weber C., et al. Expression of excision repair genes in non-malignant bone marrow from cancer patients. Mutat Res 293 (1993) 151-160
111. Britten R.A., Liu D., Tessier A., et al. ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells. Int J Cancer 89 (2000) 453-457
112. Dabholkar M., Vionnet J., Bostick-Bruton F., et al. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 94 (1994) 703-708
113. Metzger R., Leichman C.G., Danenberg K.D., et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 16 (1998) 309-316
114. Shirota Y., Stoehlmacher J., Brabender J., et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 19 (2001) 4298-4304
115. Quinn J.E., Kennedy R.D., Mullan P.B., et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 63 (2003) 6221-6228
116. Taron M., Rosell R., Felip E., et al. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet 13 (2004) 2443-2449
117. Rosell R., Danenberg K.D., Alberola V., et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 10 (2004) 1318-1325
118. Rosell R., Scagliotti G., Danenberg K.D., et al. Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene 22 (2003) 3548-3553
119. Davidson J.D., Ma L., Flagella M., et al. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res 64 (2004) 3761-3766
120. Williams T.M., and Lisanti M.P. Caveolin-1 in oncogenic transformation, cancer, and metastasis. Am J Physiol Cell Physiol 288 (2005) C494-C506
121. Kim H.A., Kim K.H., and Lee R.A. Expression of caveolin-1 is correlated with Akt-1 in colorectal cancer tissues. Exp Mol Pathol 80 (2006) 165-170
122. Yang C.P., Galbiati F., Volonte D., et al. Upregulation of caveolin-1 and caveolae organelles in Taxol-resistant A549 cells. FEBS Lett 439 (1998) 368-372
123. Sunaga N., Miyajima K., Suzuki M., et al. Different roles for caveolin-1 in the development of non-small cell lung cancer versus small cell lung cancer. Cancer Res 64 (2004) 4277-4285
124. Bajorin D.F., Bellmunt J., Bochner B.H., et al. Changing paradigms in advanced bladder cancer. ASCO Bladder Educational Book (2005) 330-350
125. Sanchez-Carbayo M., Socci N.D., Charytonowicz E., et al. Molecular profiling of bladder cancer using cDNA microarrays: Defining histogenesis and biological phenotypes. Cancer Res 62 (2002) 6973-6980
126. Dyrskjot L., Thykjaer T., Kruhoffer M., et al. Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet 33 (2003) 90-96
127. Primdahl H., Wikman F.P., von der Maase H., et al. Allelic imbalances in human bladder cancer: Genome-wide detection with high-density single-nucleotide polymorphism arrays. J Natl Cancer Inst 94 (2002) 216-223
128. Thykjaer T., Workman C., Kruhoffer M., et al. Identification of gene expression patterns in superficial and invasive human bladder cancer. Cancer Res 61 (2001) 2492-2499
129. Sanchez-Carbayo M., and Cordon-Cardo C. Applications of array technology: identification of molecular targets in bladder cancer. Br J Cancer 89 (2003) 2172-2177
130. Duggan B.J., McKnight J.J., Williamson K.E., et al. The need to embrace molecular profiling of tumor cells in prostate and bladder cancer. Clin Cancer Res 9 (2003) 1240-1247
131. Sanchez-Carbayo M., Socci N.D., Lozano J., et al. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol 24 (2006) 778-789